New study aims to improve lung cancer care for black patients
NCT ID NCT06745882
Summary
This study is testing how well the immunotherapy drug pembrolizumab, with or without chemotherapy, works for Black patients with advanced non-small cell lung cancer. It aims to see how long patients live and how long the cancer stays controlled, while also looking for markers in the blood that might predict who responds best to treatment. The goal is to gather real-world data to help improve care for this specific patient group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baptist Clinical Research Institute
RECRUITINGMemphis, Tennessee, 38120, United States
Contact
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21287, United States
Contact
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
-
TidalHealth Peninsula Regional
RECRUITINGSalisbury, Maryland, 20801, United States
Contact
Conditions
Explore the condition pages connected to this study.